William Blair Analysts Reduce Earnings Estimates for SLP

Simulations Plus, Inc. (NASDAQ:SLP) – Equities research analysts at William Blair lowered their Q1 2026 earnings estimates for shares of Simulations Plus in a research report issued to clients and investors on Monday, January 27th. William Blair analyst M. Smock now forecasts that the technology company will earn $0.16 per share for the quarter, down from their previous forecast of $0.17. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q2 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.41 EPS and FY2026 earnings at $1.32 EPS.

Several other brokerages have also recently commented on SLP. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. KeyCorp upped their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. BTIG Research decreased their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

Simulations Plus Price Performance

Shares of Simulations Plus stock opened at $33.99 on Wednesday. The stock has a market capitalization of $682.86 million, a P/E ratio of 84.98 and a beta of 0.80. The business has a 50 day simple moving average of $30.19 and a two-hundred day simple moving average of $32.70. Simulations Plus has a 12 month low of $24.00 and a 12 month high of $51.22.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 19.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Simulations Plus

Several large investors have recently modified their holdings of the business. First Horizon Advisors Inc. raised its holdings in Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after buying an additional 370 shares during the period. nVerses Capital LLC raised its stake in shares of Simulations Plus by 1,100.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after acquiring an additional 1,100 shares during the period. Quantbot Technologies LP acquired a new position in shares of Simulations Plus in the 3rd quarter worth approximately $59,000. US Bancorp DE lifted its holdings in shares of Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after acquiring an additional 1,343 shares during the last quarter. Finally, Pitcairn Co. boosted its position in shares of Simulations Plus by 9.1% during the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock worth $211,000 after purchasing an additional 549 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.